Trial Profile
Study of efficacy and safety of apatinib in Ewing sarcoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions; Therapeutic Use
- 20 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology